High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 433-435

  Giraud, Carole ^a,b,c   Manceau, Sandra ^a,b,c   Oualha, Mehdi ^b,c,e   Chappuy, Hélène ^b,c,e   Mogenet, Agnès ^c   Duchêne, Patrick ^d   Ducrocq, Sarah ^c   Hubert, Philippe ^b,e   Treluyer, Jean M ^a,b,c  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d Eurofins Medinet Inc   (Germany)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CRITICAL ILLNESS; CYSTIC FIBROSIS; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IC 50; INFANT; INFLUENZA A (H1N1); INTENSIVE CARE UNIT; PANDEMIC INFLUENZA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CRITICAL ILLNESS; FEMALE; HUMANS; INFANT; INFLUENZA, HUMAN; INTENSIVE CARE UNITS; INTUBATION, GASTROINTESTINAL; MALE; OSELTAMIVIR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78650660380     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00813-10     Document Type: Article

References (21)

1. Abe, M., J. Smith, A. Urae, J. Barrett, H. Kinoshita, and C. R. Rayner. 2006. Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann. Pharmacother. 40:1724-1730.
2. Acosta, E. P., P. Jester, P. Gal, J. Wimmer, J. Wade, R. J. Whitley, and D. W. Kimberlin. 2010. Oseltamivir dosing for influenza infection in premature neonates. J. Infect. Dis. 202:563-566.
3. Ariano, R. E., D. S. Sitar, S. A. Zelenitsky, R. Zarychanski, A. Pisipati, S. Ahern, S. Kanji, J. Rello, and A. Kumar. 2010. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 182:357-363.
4. Bantia, S., C. D. Parker, S. L. Ananth, L. L. Horn, K. Andries, P. Chand, P. L. Kotian, A. Dehghani, Y. El-Kattan, T. Lin, T. L. Hutchison, J. A. Montgomery, D. L. Kellog, and Y. S. Babu. 2001. Comparison of the antiinfluenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167.
5. Brewster, M., J. R. Smith, R. Dutkowski, and R. Robson. 2006. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study. Vaccine 24:6660-6663.
6. Cooper, N. J., A. J. Sutton, K. R. Abrams, A. Wailoo, D. Turner, and K. G. Nicholson. 2003. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 326:1235.
7. Dutkowski, R. 2010. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. J. Antimicrob. Chemother. 65(Suppl. 2): ii11-ii24.
8. Dutkowski, R., J. R. Smith, and B. E. Davies. 2010. Safety and pharmacokinetics of oseltamivir at standard and high dosages. Int. J. Antimicrob. Agents 35:461-467.
9. Dutkowski, R., B. Thakrar, E. Froehlich, P. Suter, C. Oo, and P. Ward. 2003. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 26:787-801.
10. Halasa, N. B. 2010. Update on the 2009 pandemic influenza A H1N1 in children. Curr. Opin. Pediatr. 22:83-87.
11. He, G., J. Massarella, and P. Ward. 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37:471-484.
12. Karie, S., V. Launay-Vacher, N. Janus, H. Izzedine, and G. Deray. 2006. Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. Nephrol. Dial. Transplant. 21:3606-3608.
13. Kimberlin, D. W., M. Shalabi, M. J. Abzug, D. Lang, R. F. Jacobs, G. Storch, J. S. Bradley, K. C. Wade, O. Ramilo, J. R. Romero, M. Shelton, C. Leach, J. Guzman-Cottrill, J. Robinson, N. Abughali, J. Englund, J. Griffin, P. Jester, G. A. Cloud, and R. J. Whitley. 2010. Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr. Infect. Dis. J. 29:195-198.
14. Libster, R., J. Bugna, S. Coviello, D. R. Hijano, M. Dunaiewsky, N. Reynoso, M. L. Cavalieri, M. C. Guglielmo, M. S. Areso, T. Gilligan, F. Santucho, G. Cabral, G. L. Gregorio, R. Moreno, M. I. Lutz, A. L. Panigasi, L. Saligari, M. T. Caballero, R. M. Egues Almeida, M. E. Gutierrez Meyer, M. D. Neder, M. C. Davenport, M. P. Del Valle, V. S. Santidrian, G. Mosca, M. Garcia Dominguez, L. Alvarez, P. Landa, A. Pota, N. Bolonati, R. Dalamon, V. I. Sanchez Mercol, M. Espinoza, J. C. Peuchot, A. Karolinski, M. Bruno, A. Borsa, F. Ferrero, A. Bonina, M. Ramonet, L. C. Albano, N. Luedicke, E. Alterman, V. Savy, E. Baumeister, J. D. Chappell, K. M. Edwards, G. A. Melendi, and F. P. Polack. 2010. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N. Engl. J. Med. 362:45-55.
15. Nicholson, K. G., F. Y. Aoki, A. D. Osterhaus, S. Trottier, O. Carewicz, C. H. Mercier, A. Rode, N. Kinnersley, and P. Ward. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355: 1845-1850.
16. Poehling, K. A., K. M. Edwards, G. A. Weinberg, P. Szilagyi, M. A. Staat, M. K. Iwane, C. B. Bridges, C. G. Grijalva, Y. Zhu, D. I. Bernstein, G. Herrera, D. Erdman, C. B. Hall, R. Seither, and M. R. Griffin. 2006. The underrecognized burden of influenza in young children. N. Engl. J. Med. 355:31-40.
17. Reddy, D. 2010. Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir. J. Antimicrob. Chemother. 65(Suppl. 2):ii35-ii40.
18. Shun-Shin, M., M. Thompson, C. Heneghan, R. Perera, A. Harnden, and D. Mant. 2009. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ 339:b3172.
19. Taylor, W. R., B. N. Thinh, G. T. Anh, P. Horby, H. Wertheim, N. Lindegardh, M. D. de Jong, K. Stepniewska, T. T. Hanh, N. D. Hien, N. M. Bien, N. Q. Chau, A. Fox, N. M. Ngoc, M. Crusat, J. J. Farrar, N. J. White, N. H. Ha, T. T. Lien, N. V. Trung, N. Day, and N. G. Binh. 2008. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One 3:e3410.
20. Treanor, J. J., F. G. Hayden, P. S. Vrooman, R. Barbarash, R. Bettis, D. Riff, S. Singh, N. Kinnersley, P. Ward, and R. G. Mills. 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283:1016-1024.
21. Whitley, R. J., F. G. Hayden, K. S. Reisinger, N. Young, R. Dutkowski, D. Ipe, R. G. Mills, and P. Ward. 2001. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20:127-133.